Podcasts about pcsk9

This week, Dr. Kahn provides details on presentations just made and published at the annual scientific meeting of the American Heart Association in New Orleans. Topics include a polypill for heart failure, coffee for atrial fibrillation, an oral PCSK9 inhibitor, beta-blockers after heart attacks, gene editing to lower cholesterol, and the use of PCSK9 inhibitors (Repatha) in a randomized trial of patients at risk for heart attack and stroke.  Dr. Kahn also reviews the role of lycopene in preventing prostate cancer (think tomatoes), colchicine in heart patients, the power of combining statins with ezetimibe, earlier mitral valve repairs, and new data suggesting that drugs like tadalafil (Cialis) may reduce the risk of death and dementia.  Dr. Kahn thanks tryauri.com/drkahn for their support and discount for listeners of Heart Doc VIP.

Program notes:0:50 Fish oil supplements and hemodialysis1:50 1200 individuals to fish oil or not2:50 Needs another study3:11 PCSK9 inhibitor in people without MI or stroke4:13 3- or 4-point MACE5:11 Getting LDL down helps6:11 Addition of more than one oral agent6:50 Right therapy for afib and a stent7:50 Noninferiority trial8:50 After 12 months single agent works9:27 Anticoagulation after afib tx10:30 Low primary safety outcomes11:25 96% won't have a stroke12:16 End

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Special Edition of the JAMA Editor's Summary featuring JAMA Network articles published at the 2025 AHA Scientific Sessions. Hosted by JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation DASH-Patterned Groceries and Effects on Blood Pressure Coronary Computed Tomography Angiography in Prediction of First Coronary Events Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy Clonal Hematopoiesis and Incident Heart Failure Chronic Kidney Disease Prevalence and Awareness Among US Adults Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer Prenatal Care and Perinatal Regionalization for Congenital Heart Defects Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

We have the second episode in a series of conversations with Dr. Thomas Dayspring today.  The esteemed Dr. Dayspring is an expert on internal medicine and clinical lipidology. In this episode, we continue with our last conversation, diving into Lp(a) and the influences of gender, race, and menopause. We explain how estrogen is a PCSK9 inhibitor and explore the significance of brain health and risks for dementia. We tackle cholesterol synthesis and discuss the side effects of statins, clarifying who is most susceptible to their impact on the brain. We also examine the significance of the desmosterol biomarker, highlighting the level to aim for, especially when making decisions regarding cholesterol medications, and we answer one question from a listener.  You may want to listen to this insightful conversation with the renowned Dr. Dayspring more than once. He has graciously agreed to return and film additional episodes, where we will dive into more questions from listeners.  IN THIS EPISODE, YOU WILL LEARN: Why Lp(a) is like a wolf in sheep's clothing for many individuals How Lp(a) levels are higher in African Americans and women, especially after menopause  Dr. Dayspring highlights that Lp(a) particles are even more pro-inflammatory than LDL particles How PCSK9 inhibitors are the only drugs that significantly reduce Lp(a) Why do women have a higher risk of dementia than men? Dr. Dayspring explains ApoE as the key lipoprotein for brain cholesterol transport. How statins cross the blood-brain barrier to lower brain cholesterol Why desmosterol levels matter New therapies that can lower ApoB and Lp(a) Why imaging is essential for menopausal women with elevated ApoB and Lp(a) Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Thomas Dayspring On X (@Drlipid) On LinkedIn Journal Article: Atherosclerosis: Non-genetic influences on lipoprotein(a) concentrations  Journal of the American Heart Association: Trajectories of Blood Lipid Profiles in Midlife Women: Does Menopause Matter?

In this Healthed lecture, Dr Robert Hungerford discusses the latest evidence-based recommendation to lower LDL-C targets even further in various at-risk groups, as well as the most effective means of reaching those targets in real-world Australian clinical practice. He will also present the value of combination therapy, the value of starting combination early, the role of the newer PCSK9 inhibitors and their current PBS eligibility criteria.See omnystudio.com/listener for privacy information.

Mesa Redonda Científica en La Hoguera Podcast: https://www.youtube.com/watch?v=sMLZqvar8Z8&t=7109s&pp=ygUUcHJvZmUgY2xhdWRpbyBuaWV0byA%3D ¿Qué pasa si todo lo que creías sobre el colesterol y el riesgo cardiovascular… está incompleto? En este fragmento profundo y revelador hablamos del papel fisiológico del LDL, el daño vascular, los radicales libres, la inflamación y la increíble sabiduría adaptativa del cuerpo humano. ¿Qué aprenderás en este clip? Ejercicio y Riesgo Cardiovascular El entrenamiento intenso con una mala dieta puede elevar tu presión y estrés oxidativo. ¿Cómo afecta eso a tus arterias? ⚡ Mitocondrias, ROS y Radicales Libres Tu mitocondria genera energía… y también señales inmunes. Aprende por qué los radicales libres no siempre son malos. ️ LDL, el “colesterol malo”, como antioxidante vital Cuando el cuerpo no da abasto, el LDL interviene como escudo biológico. ¿Y si tu colesterol alto fuera una estrategia de supervivencia? El daño al glicocálix arterial El exceso de oxidación daña tu barrera protectora. Sin glicocálix, ni el LDL puede ayudarte. PCSK9 y el papel del hígado Tu hígado regula el LDL según tus niveles de estrés oxidativo. Descubre el rol real de esta proteína clave (y cómo la industria farmacéutica la ha convertido en negocio). Alostasis y fisiología predictiva Los niveles de colesterol cambian según tu contexto: infección, inflamación, ayuno, deporte… Tu cuerpo no hace nada al azar. Conclusión: El LDL no es un enemigo, es un mensajero. Lo peligroso es no entenderlo. Este episodio es una defensa de la fisiología humana como una sinfonía perfecta… mal interpretada por muchos. Fragmento del episodio completo de La Hoguera Podcast, un espacio de conversación real, sin filtros, sobre ciencia, salud y rendimiento. Déjanos tu opinión, comparte con quien lo necesita, y suscríbete para más mesas redondas

Efficacy And Safety of AZD0780, An Oral Small Molecule PCSK9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

In this special JACC lipid-focused issue, Dr. Valentin Fuster explores groundbreaking global research on lipoprotein(a), its complex role in cardiovascular disease across populations, and the promising future of targeted therapies. From massive Chinese cohort studies to a novel oral PCSK9 inhibitor trial, this episode highlights the frontlines of lipid science shaping tomorrow's heart health.

This month on Episode 72 of Discover CircRes, host Cindy St. Hilaire highlights four articles featured in the April 25th and May 9th issues of Circulation Research. This Episode also includes a discussion with Dr Sarah Costantino and Dr Francesco Paneni from University Hospital Zurich about their study, Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF     Article highlights: Laudette, et al. PCSK9 and Mitochondrial Cholesterol in Heart Yang, et al. Srsf3 Limits AS by Lengthening 3′ UTRs of mtARSs Li, et al.  CircCDYL Contributes to Cardiac Hypertrophy Zhakeer, et al. Treg Cells Regulate Pulmonary Venous Remodeling

If you've been anywhere near health optimization circles, you already know Ben Greenfield as a NYT bestselling author, former Ironman triathlete, coach, one of the OGs of biohacking. Today, he's my guest on the Longevity podcast.   What we discuss: Ben's new home, cold exposure, and microdosing cryotherapy ... 00:06 Writing, updating, and revising “Boundless” ... 00:09 Key updates: Self-quantification, longevity, new detox protocols ... 00:12 High-tech blood filtration and its impact ... 00:15 Daily detox strategies: Lymphatic movement, sauna, exercise ... 00:17 Ben's evolution: From strict keto to Mediterranean-style eating ... 00:21 Genetics, ancestry, and personalized nutrition lessons ... 00:23 Impact of endurance training, hormone and gut issues, recovery via flexible dieting ... 00:27 Addressing high coronary plaque: Statins, PCSK9 inhibitors, supplementation ... 00:35 Tracking heart health non-invasively (CIMT) ... 00:38 Thoughtful, limited use of pharmaceuticals for health ... 00:44 Peptides: Orals, protocols, favorites (BPC-157, TA1, etc.) ... 00:47 GLP-1 agonists: Powerful but require careful dosing ... 00:51 Biohacks gone wrong: Dosing mishaps and psychedelic stories ... 00:55 Ben's three core tips: Family time, naps, and prayer ... 00:58   Our Amazing Sponsors: Wizard Sciences - Mitoblue Everything in the formula is there to help you think clearer, move better, and stay resilient mentally and physically - Methylene Blue, NMN, PQQ, Apigenin and Ginseng. Go to wizardsciences.com and look for MitoBlue. Use code NAT15 at checkout to get 15% off your purchase.   Mitolux NEW Second Generation - This second-generation red and near-infrared light therapy panel hits all the marks. Two new wavelengths—810nm and 940nm—target brain performance, deep muscle recovery, and circulation. I use GAMA mode when I want to lock in focus, and Fireplace 2 when I want to wind down. Get a Mitolux BTS2 Sunlamp for 10% off at https://mitolux.com/NAT10, NAT10 will be automatically applied at checkout.   LVLUP - Neuro Re-Generate the world's first liposomal triple peptide formula, designed to support mental clarity, focus, and overall brain health. Visit www.lvluphealth.com and use code NAT for 10% off your order.   Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Send us a textDr. Michael Koren shares insights from his presentation at the American College of Cardiology meeting in Chicago about a groundbreaking oral PCSK9 inhibitor that could lower cholesterol by 80% when combined with a statin. The development represents a significant advancement in treatment options for the 20% of patients who don't respond adequately to statins alone or experience statin intolerance. They also chat about Chicago and the importance of things in moderation.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Audio roundup of selected biopharma industry content from Scrip over the business week ended 4 April 2025. In this episode: pharma dodges tariffs for now; Marks's departure from FDA rattles industry; Phase 2b win for AstraZeneca's oral PCSK9; Hengrui renews global Phase 3 push; and Novo's new cardio results for semaglutide. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MPJF4YP4NFAQ5JEDFBEIW62LBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.

Μαζί με τον κ. Κοσκινά εστιάζουμε στις σύγχρονες θεραπευτικές στρατηγικές για τη δυσλιπιδαιμία, ξεκινώντας με τη συζήτηση γύρω από τις στατίνες και την εζετιμίμπη: ποια είναι η προτιμότερη προσέγγιση — συνδυασμός μέτριας έντασης στατίνης με εζετιμίμπη ή υψηλής έντασης στατίνη;Αναλύεται επίσης η θέση του μπεμπεδοϊκού οξέος, καθώς και η ραγδαία εξέλιξη των PCSK9 αναστολέων, από τα μονοκλωνικά αντισώματα στους RNA-based παράγοντες όπως το Inclisiran, έως τις νέες θεραπείες τρίτης γενιάς (π.χ. Lerodalcibep) και τις πρώτες προσπάθειες γονιδιακής θεραπείας με CRISPR.Η συζήτηση επεκτείνεται σε νεότερες κατηγορίες, όπως οι αναστολείς ANGPTL3 (π.χ. Evinacumab) και αναστολείς CETP (Obicetrapib), εξετάζοντας τη μελλοντική τους θέση στην καρδιαγγειακή πρόληψη.Τέλος, εξετάζονται οι εξελίξεις στην αντιμετώπιση της λιποπρωτεΐνης (a), με ελπιδοφόρα φάρμακα όπως τα Pelacarsen, Olpasiran, Lepodisiran, και το ανερχόμενο Muvalaplin, και γίνεται αναφορά στις αναμενόμενες νέες κατευθυντήριες οδηγίες και τις πιθανές αλλαγές που αυτές θα φέρουν.

An overview of current and emerging PCSK9-directed therapies; their efficacy, safety, and role in clinical practice. Full text of the manuscript is available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.4635.

In this podcast, expert clinicians will review the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in reducing low-density lipoprotein cholesterol (LDL-C) and reducing cardiovascular risk. https://healio.com/cme/mededtalks/cardiology/20250102/4-lipid-legends-with-your-host-dr-ronald-codario-featuring-dr-peter-toth-pcsk9-inhibition

A discussion on statins vs. PCSK9 inhibitors; My doctor said I should take a multivitamin instead of the long list of supplements I currently take. What do you think?

This is a replay of one of the most-downloaded episodes of AGE BETTER in 2024.     Take a deep dive into the heart of midlife cardiovascular wellness with this important episode of "Age Better," where host Barbara Hannah Grufferman talks with Dr. Melissa Tracy, a top-tier cardiologist from the RUSH University Medical Center. Dr. Tracy is also the Medical Director of the Cardiac Rehabilitation Program at RUSH.     Dr. Tracy gives a masterclass on statins - those powerhouse medications at the forefront of cholesterol management and heart disease prevention. But the question that lies at the core of this discussion is one that resonates with millions: Who really needs to be on statins? By tuning in, you'll get the knowledge and tools you need to make the decision that is right for you.     KEY TAKEAWAYS:  Understanding Statins: Learn how these powerful medications aid in reducing cholesterol and preventing cardiovascular disease.    Postmenopause and Heart Health: Discover the unique impact of statins for women in midlife.    Shared Decision-Making: The importance of patient-doctor collaboration in deciding if statins are right for you.    Coronary Calcium Score: Uncover how this test is crucial in assessing cardiovascular risks.    Side Effects & Alternatives: Insights into common side effects of statins and who should avoid them, plus a look at natural supplements and other cholesterol management strategies.    Personalized Healthcare: Dr. Tracy emphasizes individualized treatment plans and the role of lifestyle changes alongside statins.    Future-Focused Discussion: A sneak peek into ongoing assessments and evolving conversations in heart health management.    KEY LINKS:  Learn More About Dr. Melissa Tracy: https://doctors.rush.edu/details/1183  What is Cardiac Rehabilitation? https://www.kevinmd.com/2024/02/a-people-first-approach-to-cardiac-rehabilitation.html  USNews+WorldReport Article: https://www.usnews.com/news/health-news/articles/2024-03-05/statin-meds-cholesterol-what-you-need-to-know  Alternatives to Statins Referenced During the Episode:   Ezetimibe: https://www.mayoclinic.org/drugs-supplements/ezetimibe-oral-route/description/drg-20067172  Bempedoic Acid: https://www.mayoclinic.org/drugs-supplements/bempedoic-acid-oral-route/side-effects/drg-20484223?p=1  PCSK9 inhibitors: https://www.medicalnewstoday.com/articles/pcsk9-inhibitor#definition    Whether you're on a statin already, or giving it serious consideration … this episode will help you make the decision that is right for you.    Listen and Subscribe   Remember to subscribe or follow the "Age Better with Barbara Hannah Grufferman" podcast on platforms like Apple Podcasts, Spotify, and YouTube. Yep, you can watch it or just listen!     Share Your Ideas and Questions   Your questions have spurred many episodes, so please keep them coming! Share your ideas for topics and guest suggestions at agebetterpodcast@gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

“It's about symptoms and how you're doing and how you're feeling. It's not necessarily the number on the lab tests,” says Amy Killen, M.D. Amy Killen, M.D., a leading anti-aging and regenerative physician, joins us today to discuss science-backed methods to improve longevity, including stem cell therapies, hormone replacement, and more:  - Women's longevity stack (~2:00) - Hormone health (~4:40) - Hormone replacement therapy (HRT) (~6:05) - Different types of HRT (~7:37) - Killen's story (~9:07) - Stem cell therapy (~11:01) - Sexual health and stem cells (~17:00) - Nitric oxide (~18:10) - How to measure nitric oxide levels (~20:25) - Collagen and hyaluronic acid (~22:30) - Red light and PEMF (~23:36) - Killen's daily routine (~25:15) - Overrated practices in wellness culture (~26:29) - Modern medicine for longevity benefits (~29:45) - Testosterone replacement therapy (TRT) for men (~33:20) - Popular therapies and treatments (~36:40) - The future of longevity and women's health (~42:32) Referenced in the episode:  - Keep up with her @Dr.AmyBKillen (IG, FB, TikTok) - Follow her online (www.dramykillen.com)  - Check out her company (https://hopbox.life/)  - Learn more about her clinic (www.humanauthealth.com)   - Listen to Stacy Sims, Ph.D. on the mbg podcast episode #514  - Research on SGLT2 inhibitors (https://doi.org/10.1016/j.pcad.2023.10.003)  - Research on PCSK9 inhibitors (https://doi.org/10.1016/j.ajpc.2024.100701)  immy is a natural, effective solution to retune your immune system, while addressing inflammatory status and improving mental health and overall resilience.* Learn more about immy today at immy.co. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. ​We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

0:00- Intro               0:30- PhD process               8:00- Repetitiveness in expertise               14:40- Saturated fat, LDL, and ApoB               41:00- Statins, PCSK9 inhibitors               47:00- Human equivalent doses 

CardioNerds Dan Ambinder and Dr. Devesh Rai join cardiology fellows and National Lipid Association lipid scholars Dr. Jelani Grant from Johns Hopkins University and Dr. Alexander Razavi from Emory University. They discuss a case involving a patient with familial hypercholesterolemia. Dr. Archna Bajaj from University of Pennsylvania provides expert commentary. Drs. Jelani Grant and Alexander Razavi drafted notes. CardioNerds Intern Pacey Wetstein engineered episode audio. This episode is part of a case reports series developed in collaboration with the National Lipid Association and their Lipid Scholarship Program, with mentorship from Dr. Daniel Soffer and Dr. Eugenia Gianos. A classic finding in patients with familial hypercholesterolemia is the presence of markedly elevated levels of total and low-density lipoprotein cholesterol (LDL-C) with an LDL-C concentration of 190 mg/dL or greater. However, severe hypercholesterolemia is not inevitably present, and many patients who carry this diagnosis may have lower LDL-C levels. This case history describes a young woman whose mother and brother met clinical and genetic criteria for heterozygous familial hypercholesterolemia but who had only a mild elevation in LDL-C, falling to 130 mg/dL after dietary intervention. Despite this finding, genetic testing revealed the presence of the same genetic variants as were noted in her mother and brother. In addition, a second genetic variant predisposing them to cholesterol gallstone formation was identified in all three family members. If genetic testing had not been performed, the diagnosis may have been missed or delayed, resulting in an increased risk for vascular complications associated with familial hypercholesterolemia. This case supports the value of genetic testing of family members of those with familial hypercholesterolemia, even when LDL-C levels are not severely elevated. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association Familial hypercholesterolemia (FH) is among the most common autosomal co-dominant genetic conditions (approximately 1:200 to 1:300 for HeFH, 1:160,000 to 1:300,000 for HoFH). Genetic testing has a role for all first-degree relatives when a family history of FH is strongly suggestive, regardless of LDL-C level. Heterogeneity in ASCVD risk among individuals with FH is derived from background polygenic risk, clinical risk factors (e.g., timing of lipid-lowering initiation and adjacent risk factors), as well as subclinical atherosclerosis burden. In clinical or genetically confirmed FH, an LDL-C goal of 55 mg/dL is recommended. Beyond statins, FDA-approved non-statin therapies for FH include ezetimibe, PCSK9 mAb, bempedoic acid, inclisiran, evolocumab (only HoFH), lomitapide (only HoFH), and LDL apheresis. Notes - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association What are the diagnostic criteria for FH? Dutch Lipid Clinic Network1 Variables: family history, clinical history, physical exam, LDL-C level, DNA (LDLR, APOB, PCSK9) Simon-Broome1 Variables: total or LDL-C, physical exam, DNA (LDLR, APOB, PCSK9), family history Emphasis on clinical history and physical exam reduces sensitivity U.S. Make Early Diagnosis Prevent Early Death (MEDPED) 1 Only one of the three where no genetic testing is required, may work well in cascade screening Variables: age, total cholesterol, family relative (and degree) with FH Definite, probable, possible, unlikely Emphasis on clinical history and physical exam reduces sensitivity

Doctor Shawn Baker Key points for quick navigation: 00:01 Dr. Shawn Baker began his carnivore diet journey in late 2016 out of curiosity and health concerns, starting with a single meal and gradually transitioning. 04:23 Vitamin C deficiency (scurvy) is not observed in carnivore diets due to efficient utilization and presence in meat, contrary to common misconceptions. 07:39 Fiber is non-essential and its health benefits are likely associated with dietary quality rather than fiber itself, often improving on carnivore diets. 13:23 Meat contains a wide array of phytonutrients, challenging the notion that only fruits and vegetables provide essential nutrients. 16:11 Normative ranges for thyroid function tests (like TSH) may not reflect individual health outcomes effectively, emphasizing clinical function over lab numbers. 19:26 Dr. Shawn Baker emphasizes that he focuses on how he feels rather than just lab numbers, highlighting individual health over standardized ranges. 19:53 ️‍️ Despite having low normal testosterone levels, Shawn Baker attributes his strength and health to lifestyle factors like exercise and diet, suggesting sensitivity to androgen receptors. 20:37 Shawn Baker discusses the limitations of standard reference ranges in health metrics, advocating for more personalized approaches especially in populations like carnivores. 27:30 ️ Dr. Baker critiques the conventional focus on LDL cholesterol levels, pointing out historical biases and financial interests in promoting certain health narratives. 29:06 Discussing medication, Dr. Shawn Baker predicts potential class action lawsuits against drugs like PCSK9 inhibitors due to adverse effects like muscle loss, highlighting ethical concerns in pharmaceutical practices. 38:12 Using GLP-1 receptor agonists like semaglutide (OIC) can lead to GI side effects and potential long-term digestive issues. 39:23 Beef isolate effectively stimulates GLP-1, slowing down digestion in a natural way, contrasting with drugs like semaglutide. 41:02 GLP-1 receptor agonists may lead to fat cell hyperplasia, increasing the number of small fat cells, potentially causing weight regain after treatment cessation. 47:30 High-protein diets, contrary to common belief, do not adversely affect kidney health and may even improve kidney function in certain cases. 54:10 Eating plant-based is not necessarily environmentally superior to consuming animal products; the sustainability of agricultural practices matters more than the type of diet. 56:39 Dr. Baker emphasizes the importance of measuring nutrition and human thriving rather than just calories or environmental impact when evaluating food choices. 57:46 ️‍️ He advocates for a healthier population, criticizing societal health disparities despite abundant resources, urging for national campaigns promoting nutrition and fitness. 58:56 ️ Dr. Baker discusses how consumer choices impact public health and healthcare systems, encouraging mindful purchasing to support healthier lifestyles. 01:00:35 He reflects on the values and lifestyles of societal leaders, contrasting personal health standards with those of the general population. 01:03:34 Dr. Baker underscores the need for healthcare paradigm shifts driven by grassroots movements, highlighting the importance of patient support in effecting systemic change. https://www.revero.com/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Link to Buck's Results: https://drive.google.com/file/d/19BJaZNYwBxlPx4nR9695Q2NC3nNpgW6y/view?usp=sharing  https://drive.google.com/file/d/1br1ikAJKmgKev9X3jkS7nUPdXpAqMzYd/view?usp=sharing Section 1: Overview of Cholesterol Metabolism Cholesterol in the Body: Cholesterol is essential for cell membrane integrity, hormone synthesis, and bile acid production. It is produced endogenously in the liver and absorbed exogenously from dietary sources. Endogenous Production: Cholesterol is synthesized in the liver through the mevalonate pathway. Key intermediates: Lathosterol and Desmosterol, indicators of cholesterol production rate. Exogenous Absorption: Dietary cholesterol is absorbed in the intestines along with plant sterols like Beta-sitosterol and Campesterol. These sterols compete with cholesterol for absorption, reflecting dietary cholesterol absorption levels. Section 2: Detailed Analysis of the Test Components Production Markers: Lathosterol: Precursor in the cholesterol biosynthesis pathway. Elevated levels indicate increased hepatic cholesterol synthesis (overproduction). Example: Lathosterol level of 329 µmol x 100/mmol in my study indicates hyperactive cholesterol production. Desmosterol: Another precursor in the synthesis pathway, contributing to total cholesterol production. High levels reinforce the diagnosis of increased cholesterol production. Example: Desmosterol level of 74 µmol x 100/mmol in my study supports elevated production. Absorption Markers: Beta-sitosterol: Plant sterol absorbed in the intestines, competes with cholesterol. High levels suggest increased absorption of dietary cholesterol. Example: Beta-sitosterol level of 120 µmol x 100/mmol indicates borderline absorption. Campesterol: Similar to Beta-sitosterol, reflects cholesterol absorption efficiency. Elevated levels indicate increased absorption. Example: Campesterol level of 113 µmol x 100/mmol within normal limits but suggests absorption could be a factor. Cholesterol Balance Score: Ratio of production to absorption markers. A higher score indicates predominant cholesterol production; a lower score indicates absorption as the main issue. Example: Score of 2.4 suggests overproduction is the dominant issue. Section 3: Clinical Implications and Treatment Strategies (10 minutes) Frequency of Overproduction vs. Overabsorption: Common to see patients with either overproduction or overabsorption, but less commonly both. Overproducers: Significant portion of hypercholesterolemia patients, especially those with genetic conditions like Familial Hypercholesterolemia. Overabsorbers: Often have high-cholesterol diets or genetic predispositions. Treatment Implications: Overproducers: Statins are first-line treatment; they inhibit HMG-CoA reductase in cholesterol synthesis. Overabsorbers: Ezetimibe, which inhibits intestinal cholesterol absorption, can be effective. Combination Therapy: Considered for mixed dyslipidemia cases. Case Examples: Example of a patient with high production markers but borderline absorption: Statin therapy may be appropriate, with potential addition of Ezetimibe. Example of a patient who is a high absorber but not a high producer: Dietary changes and Ezetimibe might suffice without statins. Section 4: Physiological Mechanisms and Genetic Considerations Pathophysiology of Cholesterol Production: Overproduction may result from genetic mutations (LDL receptor or PCSK9) or conditions like insulin resistance. Pathophysiology of Cholesterol Absorption: Increased absorption could be due to genetic polymorphisms (NPC1L1 gene), leading to higher dietary cholesterol absorption. Section 5: Practical Application in Clinical Practice Incorporating the Test into Clinical Workflow: Integrate the Boston Heart Cholesterol Balance Test for patients with unexplained hypercholesterolemia or non-responders to standard therapy. Tailor treatment based on whether a patient is an overproducer, an overabsorber, or both. Patient Communication: Explain test results in an understandable way, emphasizing personalized treatment plans.

Please Subscribe and Review: Apple Podcasts | RSS Submit your questions for the podcast here News Topic: "History Comes In Patterns" Neil Howe: Civil War, Market Crashes, and The Fourth Turning | PBD #441 Show Notes: The Fourth Turning Is Here: What the Seasons of History Tell Us about How and When This Crisis Will End Elevated levels of serum per- and poly-fluoroalkyl substances (PFAS) in contact lens users of U.S. young adults Questions:    PFOAS in Contacts Chrissy writes: Good day, I know pfoas are everywhere but contacts too! I hate wearing glasses. Additionally most are UV blocking, which is something I want in my eyes. Should contacts be ditched! What do you or your family do?   Choosing a Functional Doc Chris writes:  Hello, Long time fan boy... Any advice on picking a good functional medicine doctor in my local area? Google search? Anything to look for, or look out for? I found a local MD with a long time in family medicine, who transitioned to integrative holistic medicine about 10 years ago, and then got an ABoIM about 5 years ago. I can only assume that ABoIM is a board certificate of some kind? Sounds like integrative medicine is similar to functional medicine? I ask because I have become a moody AF little bitch after a year on a statin. My original family doc and my precision health report says the cholesterol is on the risky to highly risky side of things. I have always wanted to get off of the statin, and try the PCSK9 inhibitor you discussed some months back. Finally aiming to start that transition. Any help or advice on doc selection is appreciated! Cheers, Chris R   Sponsor: The Healthy Rebellion Radio is sponsored by our electrolyte company, LMNT. Proper hydration is more than just drinking water. You need electrolytes too! Check out The Healthy Rebellion Radio sponsor LMNT for grab-and-go electrolyte drink mix packets and the new LMNT Sparkling electrolyte performance beverage! Click here to get your LMNT electrolytes Transcript: Coming soon!  

Send us a Text Message.What if understanding cholesterol and triglycerides could dramatically improve your health? This episode is a thorough and in-depth discussion where Dr. Michael Koren sheds light on the intricate relationship between genetics, diet, and lipid levels across different ethnic groups. We'll explore why non-Hispanic whites and Mexican Americans are more prone to high triglycerides than non-Hispanic blacks and dive into the liver's pivotal role in lipid metabolism. Learn the significance of managing LDL cholesterol for high-risk patients and get insights into the ongoing challenges of raising HDL levels and the latest advancements in medications.From practical strategies to lower cholesterol and triglycerides to understanding the impact of fasting for accurate measurements, this episode covers it all. Discover how lifestyle choices, diet, and even the timing of your blood tests can affect your lipid profile. We also delve into the benefits of fish oil and new pharmacological treatments like statins and PCSK9 inhibitors. Equip yourself with the knowledge to make informed health decisions and improve your cardiovascular well-being.Talking Topics:Understanding Cholesterol and TriglyceridesLipids, Genetics, and Health InsightsLowering Cholesterol and Triglycerides AccessiblyUnderstanding Triglycerides and Diet ImpactTriglycerides, HDL, and Heart HealthOmega-3s Impact on TriglyceridesThis episode is a rebroadcast of a live event hosted at ENCORE Research Group on July 15, 2024.Be a part of advancing science by participating in clinical research.Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome to Supreme Court Opinions. In this episode, you'll hear the Court's opinion in Amgen Inc. v Sanofi. In this case, the court considered this issue: Do Amgen's two patents satisfy the Patent Act's enablement clause—that is, describing the invention with sufficient particularity that would enable a “skilled artisan” to “make and use” the claimed invention? The case was decided on May 18, 2023. The Supreme Court held that Amgen's two patent applications—purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism—fail to satisfy the Patent Act's enablement clause. Justice Neil Gorsuch authored the unanimous opinion of the Court affirming the judgment below. It is well established that the enablement requirement means that if a patent claims an entire class of process, machines, manufactures, or compositions of matter, its specification must enable a person skilled in the art to make and use the entire class. While the specification may call for a reasonable amount of experimentation to make and use a claimed invention, it must not be too broad. Amgen's specification fails to enable all that it has claimed, even allowing for a reasonable degree of experimentation. It described 26 antibodies by their amino acid sequences, but it claims to monopolize an entire class of antibodies not described. Thus, its claim is too broad. The opinion is presented here in its entirety, but with citations omitted. If you appreciate this episode, please subscribe. Thank you.  --- Support this podcast: https://podcasters.spotify.com/pod/show/scotus-opinions/support

In episode 529 of Sigma Nutrition Radio, we discuss all things related to cholesterol, atherosclerosis, heart disease, and dietary fat. The discussion extensively covers the impact of LDL cholesterol and ApoB on atherosclerotic plaque progression, cardiovascular events, and the benefits of early LDL lowering interventions, particularly through the use of PCSK9 inhibitors alongside statins. We address misconceptions prevalent in the low-carb and carnivore communities, dissect claims regarding saturated fats, and elucidate why atherosclerosis predominantly affects arteries and not veins. The episode sheds light on the nuanced mechanisms of cholesterol metabolism, the significance of different lipid particles, and the limited dietary impact on LP(a) levels. Comprehensive evidence-based insights and practical recommendations for dietary patterns and cardiovascular health interventions are provided, offering clarity on these complex topics. Note: This discussion is hosted by Simon Hill, and originally appeared as an episode of The Proof podcast. Links: Subscribe to Sigma Nutrition Premium Receive our free weekly email: the Sigma Synopsis Episode with Professor Chris Packard Timestamps: 07:19 Understanding Cholesterol and Lipoproteins 14:35 The Role of ApoB in Cardiovascular Risk 25:10 Atherogenic Lipoproteins and Their Impact 37:42 Causal Pathways and Biomarkers in Heart Disease 47:02 Understanding Residual Risk and Triglycerides 49:46 Paul Saladino's Claims on LDL and Metabolic Health 01:03:01 Addressing Concerns About Lowering Cholesterol 01:16:16 The Importance of Early Intervention in Cholesterol Management 01:23:36 The Future of Cholesterol Management and Gene Editing 01:28:24 Atherosclerosis in Arteries vs. Veins 01:36:08 Dietary Interventions to Lower ApoB Levels 01:47:55 Modifying Keto Diet for Better Health Outcomes 01:56:33 Plant-Based Diets and Fat Consumption 02:05:10 Understanding Lp(a) and Its Impact on Health Subscribe to Sigma Nutrition Premium

This case report explores the intricacies of familial hypercholesterolemia (FH), delving into its genetic basis, atherosclerotic cascade, and early-onset cardiovascular complications. It examines established diagnostic criteria and emphasizes personalized management, including statins, novel therapies, and lifestyle modifications. CardioNerds cofounders (Drs. Amit Goyal and Danial Ambinder) join Dr. Irfan Shafi, Dr. Preeya Prakash, and Dr. Rebecca Theisen from the Wayne State University/DMC and Central Michigan University at Campus Martius in Downtown Detroit for some holiday ice-skating! They discuss an interesting pediatric case (see case synopsis below). Dr. Luis C Afonso provides the Expert CardioNerd Perspectives & Review segment for this episode. Audio editing by CardioNerds academy intern, Pace Wetstein. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Synopsis FH, a 9-year-old female with no previous medical history, recently moved back to the US from Iraq. She presented to establish care and discuss new-onset chest pain and dyspnea. A systolic ejection murmur was noted during her initial visit to the pediatrician, prompting cholesterol testing and a cardiology referral. Testing revealed, alarming cholesterol levels (Total Cholesterol: 802 mg/dL, LDL: 731 mg/dL, Triglycerides: 123 mg/dL) prompted concern for cardiac involvement. Due to persistent symptoms, FH was transferred to Children's Hospital of Michigan. Despite normal findings on EKG and chest x-ray, a 2/6 systolic murmur was noted. She was discharged with a cardiology clinic follow-up. However, two days later, FH experienced severe chest pain at rest, sweating, and difficulty breathing. She was transported to Children's Hospital again, and her troponin level measured 3000, and her total cholesterol was 695 mg/dL. An echocardiogram revealed valvar and supravalvar aortic stenosis, necessitating collaboration between Pediatric and Adult cardiology teams. CTA thorax revealed severe supravalvular stenosis, a hypoplastic right coronary artery, and significant coronary artery obstructions. Diagnostic cardiac catheterization confirmed severe aortic stenosis and coronary artery disease, leading to the decision for surgical intervention. FH underwent the Ross operation, left main coronary artery augmentation, and right coronary artery reimplantation. Intraoperatively, atherosclerotic plaques were observed in multiple cardiac structures. FH's recovery was uneventful, discharged on a regimen including Atorvastatin, Ezetimibe, evolocumab, and antiplatelet therapy. Persistent high LDL levels required regular plasmapheresis. Plans for evaluations in Genetics, Lipid Clinic, Endocrine, and Gastroenterology were made, potentially leading to a liver transplant assessment. Given the severity of her condition, a heart/liver transplant might be considered in the future. Conclusion: This case of FH highlights the complex presentation of severe aortic stenosis and coronary artery disease in a pediatric patient. Urgent diagnosis, interdisciplinary collaboration, and aggressive management were crucial. The case underscores the importance of comprehensive care for pediatric patients with rare cardiac conditions, emphasizing collaboration between specialties for optimal outcomes and long-term well-being. Case Media Pearls - Familial Hypercholesterolemia Mutations in LDLR, ApoB, or PCSK9 genes disrupt LDL-C clearance, leading to a cascade of events culminating in accelerated atherosclerosis and early-onset cardiovascular complications (e.g., CAD, aortic stenosis, PAD, stroke). Diagnosis of familial hypercholesterolemia relies on ...

“Menopause is inevitable, but suffering through it is not," says Mary Claire Haver, M.D. Mary Claire, a board-certified OBGYN and certified menopause practitioner, joins us to discuss everything a woman needs to know during this hormonal transition and beyond, including: - Old vs. new menopause (~00:07) - Signs of peri menopause in 30s, 40s & 50s (~02:04) - Sleep deprivation during menopause (~05:09) - Menopause weight gain (~06:36) - How to enhance body composition as you age (~09:25) - Protein needs for women (~14:20) - The link between food & hot flashes (~16:09) - Pros & cons of hormone replacement therapy (~18:43) - How to know if you're a good candidate for HRT (~25:02) - Best questions to ask your doctor (~27:23) - Why we should have annual midlife wellness visits (~28:28) - The future of menopause care (~31:23) - A drug that can prolong estrogen production (~33:02) - How to measure estrogen swings (~35:10) - How to be your own menopause advocate (~39:35) Visit shop.mindbodygreen.com/whey20 to get 20% off whey protein isolate+. Cannot combine with gift cards or other discount codes. Referenced in the episode: - Mary Claire's book, The New Menopause - The Galveston Diet - Follow Mary Claire on Instagram - mbg Podcast episode #529, with Lisa Mosconi, Ph.D. - mbg Podcast episode #480, with Peter Attia, M.D. - Statins Peter mentions: PCSK9 inhibitors, Ezetimibe, and Bempedoic Acid - WHI study on frailty - A study on estrogen therapy & dementia - menopause.org - Mary Claire's Menopause Empowerment Guide - Tests to ask for at the doctor - Oviva Therapeutics We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Dr. Warrick Bishop discusses lowering LDL cholesterol levels and whether it is safe to lower them very low. He explains that babies are born with very low cholesterol, and people with genetic mutations also have low cholesterol without negative effects. Studies show that lowering LDL to very low levels, even under 0.2 mmol/L, significantly reduces heart disease risk without increasing other health issues. Tests found no cognitive impacts of lowering LDL cholesterol levels using PCSK9 inhibitors. While statins may slightly increase diabetes risk, other cholesterollowering drugs do not appear to have this effect when lowering cholesterol alone.

As I've been researching and writing Boundless 2.0, I've found myself reevaluating many of the health and fitness strategies that I previously endorsed.In this episode, prepare to have your perspective challenged as I discuss some of the significant shifts in thinking I've undergone while exploring the latest science and experimenting with biohacking. To kick off the show, I discuss one of the biggest areas where I've updated my thinking — the ketogenic diet. While I was previously gung-ho about strict therapeutic ketosis for all sorts of applications, I now have a more nuanced view that involves limiting carbohydrates during the day for enhanced focus and consuming 200 to 300g in the evening to support better sleep and hormonal balance. Additionally, I've moved away from a saturated fat-heavy keto diet to a Mediterranean-style approach with foods like avocados, olives, oily fish, and olive oil. When it comes to exercise, I used to be that guy who obsessively crushed two-a-day workout sessions. But the more I dig into the research, the more I've come to understand the importance of staying within the "Goldilocks Zone" — enough training to accrue benefits, but not so much that you risk overtraining. Another controversial mind shift I've experienced is around statins, which was prompted by my advanced cardiac screening. My Cleerly test revealed plaque buildup, leading me to start a PCSK9 inhibitor and a daily dose of rosuvastatin and acetamide. While I still don't think these drugs should be blindly taken, in some cases the benefits can outweigh the risks if properly monitored. My view on cold exposure has also slightly changed after digging into research. I used to be all about long ice baths and open-water cold swims, but now I've shifted to shorter, more frequent cold exposures. (You'll hear multiple times throughout this show that optimizing your body is all about finding the right balance and avoiding excessive stress.) This show also covers topics like the hidden benefits of aspirin, ginger, and yes... even "dick pills." Plus, you'll gain insights into sleep hacking, why I'm taking a more discerning stance on cannabis, and the dangers of extreme biohacking. For the full show notes, visit: https://bengreenfieldlife.com/470 Episode Sponsors: Paleovalley: Go to paleovalley.com/ben to get 15% off your first order. C60: Visit shopc60.com/ben-greenfield and use code GREENFIELD15 for 15% OFF your first order. Mito Red Light: Go to mitoredlight.com and use code BGLIFE to save 5%. Ion Layer: Use code GREENFIELD at ionlayer.com/ben for $150 off your kit and start reaping the benefits of NAD+. Jigsaw Health: Visit JigsawAC.com and use "GREENFIELD10" to get 10% off.See omnystudio.com/listener for privacy information.

Today you'll learn about a zombie virus recovered from the arctic permafrost and brought back to life, some good news about 26 Australian animal species that have been brought back from the brink, and how a new pill could potentially limit the levels of “bad” cholesterol in the body. Zombie Virus “Scientists have revived a ‘zombie' virus that spent 48,500 years frozen in permafrost.” By Katie Hunt. 2023. “Arctic permafrost is thawing rapidly. It affects us all.” By Katie Hunt. 2022. Back From the Brink “Researchers find 26 Australian species recovered from the brink of extinction.” abc.net. 2023. “Lights at the end of the tunnel: The incidence and characteristics of recovery for Australian threatened animals.” by Woinarski, et al. 2023. “Humpback whales no longer listed as endangered after major recovery.” by Claudia Long. 2022. “Red List: Summary Statistics.” n.a. N.d. Bad Cholesterol “Oral pill cuts bad cholesterol by 60% in phase 2 clinical trial” By Michael Irving “Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial” by Christie M. Ballantyne et al. “What Is the Difference Between Good and Bad Cholesterol?” by Keck Medicine of USC “Coronary artery disease” by Mayo Clinic “PCSK9 gene” by MedLine Plus Hosted on Acast. See acast.com/privacy for more information.